All episodes

In this episode, members of the EASD Committee on Clinical Affairs (CCA) discuss how clinical guidance is developed, reviewed and translated into real-world practice. CCA Chair, Prof. Richard Holt and Prof. Anne Peters explore the production of consensus reports, expert opinion documents and the EASD’s new guideline programme.

They discuss the first EASD guideline on diabetes distress, the upcoming guideline on continuous glucose monitoring in type 2 diabetes, and updates to the Type 1 diabetes consensus report. The conversation also highlights the critical role of patient involvement, public consultation and policy engagement in ensuring that guidance improves care across Europe...

In this episode, Prof. Nita Forouhi (University of Cambridge) and Prof. Michael Lean (University of Glasgow) explore the science behind nutrition, weight loss and type 2 diabetes remission. They discuss the role of ultra-processed foods, meat consumption and the importance of whole-food, minimally processed diets.

The conversation highlights groundbreaking research showing that substantial, intentional weight loss can reverse type 2 diabetes by reducing fat in organs like the liver, pancreas, and heart, restoring insulin sensitivity and pancreatic function.

They also tackle how to communicate evidence-based messages amid a flood of misinformation, and the importance of patient-centred research and guidance for...

In this episode, experts from the University of Amsterdam (Prof. J. Hans de Vries), the University of Newcastle (Prof. James A.M. Shaw) and Deakin University (Prof. Jane Speight) explore one of the most feared complications of type 1 diabetes: severe hypoglycaemia.

While advances in continuous glucose monitoring and automated insulin delivery have reduced severe episodes by around 40%, they have not eliminated the problem. The discussion examines why technology has limits, the challenges of impaired awareness and when transplantation may be considered for people with recurrent severe hypoglycaemia.

The conversation also highlights the profound psychological burden of hypoglycaemia; from trauma...

In this episode, Prof. Gill Livingston (University College London) and Prof. Thomas van Sloten (UMC Utrecht) explore the complex relationship between diabetes and dementia. People with diabetes face a higher risk of cognitive decline, particularly those with type 2 diabetes, and as treatment improves and life expectancy increases, dementia is becoming a growing clinical challenge.

The discussion examines how diabetes medications, including GLP-1 receptor agonists and SGLT2 inhibitors, may influence cognitive outcomes, the role of lifestyle and vascular risk factors, and why prevention must become central to diabetes care.

This episode also highlights the urgent need for clinical trials that...

In this episode, Professor Francesco Giorgino (EASD President) and Professor Leszek Czupryniak (EASD Global Council Advisor) introduce EASD's newest initiative: the Global Council, launched in Madrid in 2023. This 13-member council brings together diabetes experts from Asia, North and South America, Africa, the Middle East, Australia, and underrepresented regions of Europe to provide direct, active contributions to EASD activities and address global challenges in diabetes research and care.

The conversation addresses the urgent importance of diversity in diabetes data and research, particularly as political movements in some regions actively discourage it and explains how registries are essential for understanding diabetes...

In this episode, a cardiologist, an epidemiologist and a diabetologist come together to discuss the deep and evolving links between diabetes and cardiovascular disease. The conversation explores heart failure as a common but often under-recognized complication of diabetes, how cardiovascular risk begins even before type 2 diabetes develops, and why modern therapies increasingly target multiple organs at once. The speakers highlight the importance of early detection, collaboration across specialties, and prevention as populations age and chronic disease patterns shift.

In this episode, Prof. Frédéric Gachon and Prof. Olga Pivovarova-Ramich explore how the timing of eating and exercise influences metabolism and diabetes risk. Drawing on recent research in chronobiology, they discuss circadian rhythms, chronotype, late-night eating, intermittent fasting, and how aligning daily behaviours with our internal clocks may improve metabolic health and insulin sensitivity.

Prof. Gachon and and Prof. Pivovarova-Ramich explore how eating late or at the wrong time disrupts your body’s rhythm, and how different chronotypes (early risers vs night owls) respond to meal timing. They also touch on the growing popularity of intermittent fasting and time-restricted eating, as...

In this weeks episode of Diabetes Insights - Breakthroughs and Innovators, experts discuss the highly anticipated SURPASS CVOT trial, a head-to-head cardiovascular outcomes study comparing tirzepatide 15 mg weekly with dulaglutide 1.5 mg weekly in people with type 2 diabetes. With over 13,000 participants, the trial demonstrates that tirzepatide provides equivalent cardioprotective benefits to dulaglutide, confirming its role in improving both glycaemic control and cardiovascular outcomes.

EASD TV Host Vivienne Parry sits with Prof. Tina Vilsbøll (EASD Honorary Secretary) and Prof. Hertzel Gerstein (EASD Independent Advisor and McMaster University) to unpack the trial’s implications for clinical practice, highlighting how outcomes...

In our first episode of 2026, Prof. Hindrik Mulder, Editor-in-Chief of Diabetologia, offers a journal’s-eye view of the most exciting and challenging developments in diabetes research today.

Drawing on his unique overview of submissions from across the global research community, prof. Mulder discusses emerging breakthroughs such as hypoimmune stem cell-based therapies that are transforming from theoretical possibilities into scalable, off-the-shelf treatments for diabetes. Prof. Mulder discusses how these innovations could revolutionise diabetes care by overcoming the historical barriers of islet transplantation.

We further explore Diabetologia's special 2025 issue on "Opportunities and Challenges in Diabetes," which tackles the critical issues of...

In this episode, Dr. Tamara Hannon (Indiana University Health) and Prof. Martin Wabitsch (Universtätsklinikum Ulm) unpack the findings of the SURPASS-PEDS trial - the first study to evaluate the dual GIP/GLP-1 receptor agonist tirzepatide in adolescents with type 2 diabetes.

With youth-onset type 2 diabetes rising sharply across the US and Europe, and with young people experiencing faster beta-cell decline, more severe obesity, and greater socioeconomic burdens, the need for effective therapies has never been greater. They discuss why adolescent disease differs fundamentally from adult type 2 diabetes, why weight-loss expectations cannot be compared across age groups, and how tirzepatide...